Prussian blue nanoparticles prevent RANKL-induced osteoclastogenesis by scavenging ROS and inactivating NF-κB/MAPK...

Area of Science:

• Biomaterials Science
• Nanomedicine
• Bone Biology

Background:

• Intracellular reactive oxygen species (ROS) accumulation promotes osteoclast development, a key factor in osteoporosis.
• Prussian blue nanoparticles (PBNPs) exhibit potent ROS scavenging abilities and good biocompatibility.
• The therapeutic potential of PBNPs in osteoporosis remains unexplored.

Purpose of the Study:

• To investigate the efficacy of PBNPs in inhibiting osteoclast differentiation.
• To determine if PBNPs can prevent ovariectomy (OVX)-induced bone loss by suppressing ROS.
• To elucidate the underlying molecular mechanisms of PBNP action.

Main Methods:

• In vitro studies assessed osteoclastogenesis and gene expression following PBNP treatment.
• Mechanistic investigations explored PBNP effects on ROS generation, scavenging enzymes, and signaling pathways (NF-κB, ERK, JNK, p38).
• In vivo experiments utilized an OVX-induced osteoporosis mouse model to evaluate PBNP's protective effects on bone loss and ROS levels.

Main Results:

• In vitro, PBNPs attenuated osteoclastogenesis and downregulated key osteoclast-related genes.
• PBNPs reduced cellular ROS by inhibiting RANKL-induced ROS production and enhancing ROS scavenging enzymes, subsequently suppressing NFATc1 signaling via the NF-κB, ERK, JNK, and p38 pathways.
• In vivo, PBNPs significantly decreased ROS levels in the bone marrow, reduced osteoclast numbers, and protected against OVX-induced bone loss.

Conclusions:

• This study demonstrates that PBNPs effectively prevent OVX-induced bone loss and attenuate osteoclastogenesis.
• PBNPs act by suppressing ROS accumulation and modulating critical signaling pathways involved in osteoclast differentiation.
• PBNPs represent a promising therapeutic strategy for managing osteoclast-associated bone disorders like osteoporosis.